Bristol-Myers Squibb has been navigating some choppy waters but seems poised for a turnaround. Recently, shares have ticked ...

Bristol Myers Squibb appointed Nathan Pennell, MD, PhD, FASCO, as SVP, worldwide head of medical affairs for hematology and oncology, effective August 18. Nucleus RadioPharma hired former Food and ...

Bristol-Myers Squibb Company is pushing the boundaries with its latest clinical study on Deucravacitinib. The drug targets moderate to severe systemic lupus erythematosus (SLE). Employing a ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...